Jelly supplement aims to ease chemo side effects in cancer patients
NCT ID NCT07514754
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a jelly-based nutritional supplement in 52 people with head and neck, lung, or rectal cancer who are receiving standard cancer treatments like chemo or radiation. The supplement contains ingredients like arginine, omega-3, and olive oil, and is taken twice daily for up to 45 days. The goal is to see if it can reduce severe side effects and help patients stay on track with their treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Galenic Immunonutrition Formula (a jelly supplement with arginine, brewer's yeast, omega-3, olive oil, and other ingredients)
What this could lead to
If it works, this supplement could help reduce severe side effects from cancer treatments, making it easier for patients to complete their therapy.
What could go wrong
This is a small, early-phase study with no control group, so results may not be conclusive. The supplement may not reduce side effects or could cause digestive discomfort.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione del Piemonte per l'Oncologia- IRCCS Istituto di Candiolo, Candiolo, Turin 10060
RECRUITINGCandiolo, Torino (TO), 10060, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••